Last Update: Jul 10, 2024
A 2 Year, Double-blind, Randomized, Multicenter, Active-controlled Core Phase to Evaluate Safety & Efficacy of Daily Fingolimod vs Weekly Interferon β-1a im in Pediatric Patients With Multiple Sclerosis and 5 Year Fingolimod Extension Phase
ClinicalTrials.gov Identifier:
Novartis Reference Number:CFTY720D2311
All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in
pediatric patients with multiple sclerosis (MS) The study is divided into a Core Phase, which includes the Double-Blind Treatment Period,
and an Extension Phase in which all patients will be treated with fingolimod. The Core
Phase is a 24-month, double-blind, randomized, active-controlled, parallel-group
multicenter study phase to evaluate the efficacy and safety of fingolimod compared to IFN
β-1a in children/adolescent patients aged 10-17 years old with MS. The Extension Phase is
a 60-month (5 year) study phase for patients who complete the Core Phase of the study and
meet all inclusion/exclusion criteria and for patients who will be recruited in the
younger cohort to participate in the Extension Phase. The 'younger cohort' refers to the
population of pediatric patients fulfilling any single one or a combination of the
following criteria: being ≤12 years of age, or weighing ≤40 kg, or being prepubertal
(i.e. pubertal status of Tanner stage <2). The recruitment of the younger cohort (up to
25 patients) was requested as a post- approval health authority commitment

Multiple Sclerosis
Phase3
Recruiting
245
Jul 26, 2013
Jul 12, 2029
All
10 Years - 17 Years (Child)

Interventions

Drug

Fingolimod

Administrated orally once daily: 0.5 mg capsule for patients over 40 kg or 0.25 mg capsule for patients 40 kg or less.
Drug

Interferon beta-1a

Administration once weekly via i.m. injections.
Drug

Placebo capsule

Matching placebo capsule required for double-dummy masking to blind formulations.
Drug

Placebo i.m. injection

Matching placebo i.m. injection required for double-dummy masking to blind formulations.

Eligibility Criteria

Key Inclusion Criteria Core Phase:

- diagnosis of multiple sclerosis

- at least one MS relapse during the previous year or two MS relapses in the previous
2 years or evidence of Gd enhancing lesions on MRI within 6 months EDSS score of 0
to 5.5, inclusive

Key Exclusion Criteria Core Phase:

- patients with progressive MS

- patients with an active, chronic disease of the immune system other than MS

- patients meeting the definition of ADEM

- patients with severe cardiac disease or significant findings on the screening ECG.

- patients with severe renal insufficiency

Key Inclusion Criteria Extension Phase:

Applies to all patients participating in the Core Phase and then entering the Extension
Phase. 1. Patients that originally met Core Phase Inclusion criteria and completed the
Core phase on or off of study drug.

Applies to patients newly recruited to participate in the Extension Phase.

- All newly recruited patients' that enroll directly into the Extension Phase must
fulfill the local country health authority product label approved for pediatric age
group for inclusion criteria.

- Central review (including initial MRI report) of the diagnosis of pediatric MS will
be required for all newly recruited patients.

Key Exclusion Criteria Extension Phase:

Applies to patients who completed the Core Phase, but prematurely discontinued study
drug.

1. Premature discontinuation of the study drug during the Core Phase due to:

- an adverse event,

- serious adverse event,

- laboratory abnormality

- other conditions leading to permanent study drug discontinuation due to safety
reasons

2. Patients with known new events or concomitant medications (washout periods required
prior to Visit 15) that would exclude them from the Core Phase exclusion criteria.
Serological or other additional tests will not be required.

Applies to patients newly recruited in the younger cohort to participate in the Extension
Phase.

1. All newly recruited patients in the younger cohort that enroll directly into the
Extension Phase must fulfill the exclusion criteria for the core phase.

Worldwide Contacts

If the location of your choosing does not feature any contact detail, please reach out using the information below.

Novartis Pharmaceuticals

Novartis Pharmaceuticals